Global Urology Surgical Instruments Market 2026 – 2035

It is predicted that the market size of the global urology surgical instruments market will be USD 8.94 billion in 2025, and will increase to USD 9.78 billion in 2026, and approximately USD 18.42 billion in 2035, with an annual CAGR of 9.4% between 2026 and 2035.

The market has been increasing due to the increased incidences of urological diseases such as kidney stones, benign prostatic hyperplasia and urological cancers, the increase in the use of minimally invasive surgical procedures, the technological development of robotic and laser-based surgery systems, the aging population prone to urological diseases, and the rising healthcare infrastructural growth in the emerging economies.

Market Highlight

• The North American market led the urology surgical instruments market with a market share of 41.0%.

• Asia Pacific will increase by 11.7% within the period of 2026-2035.

• The endoscopes segment had captured over 28% of the market share in 2025.

• By application, the highest CAGR of 10.8% in the kidney diseases segment will be in 2026-2035.

• Surgery type-wise, the segment of minimally invasive surgery is expected to have the highest CAGR of 10.3% in the projection period, 2026-35.

• By end user, 58% of the market share was captured by hospitals in 2025.

• This is because in 2024, 24% of all urological surgeries in developed countries were robot assisted.

Significant Growth Factors

• Rising Prevalence of Urological Disorders Globally:

The increasing prevalence of urological diseases across the world has been the key driver of the urology surgical instruments market, as demographic changes, changes in lifestyles, and the advancement in detection and treatment of urinary tract disorders have contributed to the increasing prevalence of urology diseases. The world health organization indicates that about 12% of the world population is afflicted with kidney stones and the rate of prevalence has grown by 70% over the last three decades in the developed world. According to a report provided by the National Institutes of Health, there are more than 600,000 kidney stone removal procedures in the United States alone, and every single one of them involves a set of specialized equipment, such as ureteroscopes, lithotripters, and stone retrieval tools.

The BPH prevalence is 50% in the age group of 51-60 years and 90% in the age group of over 80 years, where it is reported that the outpatient visits in the US are around 4.5 million annually and 350,000 cases undergo surgery per annum today. Urological cancers are a major disease burden with bladder cancer diagnosed in 573,000 new patients annually worldwide, prostate cancer diagnosed in 1.4 million men each year, and cancer of the kidney being diagnosed in 430,000 individuals annually. It is estimated by the American Urological Association that urological conditions in the United States cost 13.6 million physician office visits, 2.8 million emergency department visits, and 1.2 million hospital discharges each year. In the world, the urinary incontinence burden is 423 million individuals and the prevalence in women above 60 and men above 65, reaches 35-40 and 20-25%, respectively, which means that there is a high demand to use these instruments and the sling procedures to provide the surgical intervention. In addition to contributing to instrument utilization rates, urinary tract infections that are medically treated need surgical intervention in 8-12% of complicated cases that include abscess formation, anatomical abnormalities, or recurrent urinary tract infections.

• Rapid Adoption of Minimally Invasive and Robot-Assisted Surgical Techniques:

The revolution in the paradigm of urologic surgery has been the replacement of open surgery with minimally invasive and robot-assisted surgery techniques, which have necessitated the sale of specific instruments to provide access to endoscopic surgery, laparoscopic surgery, and robot-assisted surgery. There was an upward trend in minimally invasive urological procedures, which went from 32% of all urological operations in 2010 to 68% in 2024 according to the preference of the surgeon, demand and clinical advantages to the patient. Intuitive Surgical produced the da Vinci Surgical System that has been implemented in more than 7,500 hospitals worldwide, and urological surgeries constitute 42% of the total volume of robotic surgery. The number of robotic-assisted operations according to 2024 is around 1.2 million worldwide with the greater amount of operations being prostatectomy, partial nephrectomy and pyeloplasty.

A clinical evidence shows that with minimal invasiveness, the length of stay has decreased from 5-7 days when using open surgery to 1-2 days when using laparoscopic surgery or robotic surgery, blood loss is decreased by 65-80%, postoperative pain can be reduced by 50% when using fewer opioid painkillers, and recovery and reintegration into normal life occur more quickly with laparoscopic surgery or robotic surgery in 75% of cases compared to 6-8 weeks after open surgery. Initial costs of robotic surgical systems are between 1.5 and 2.5 million dollars with 150,000-250,000 as maintenance expenses, but hospitals have seen positive ROI in 3-4 years due to the volume of surgeries, decreased complications and a better reputation that is attracting more patients. Single-port robotic systems with surgery through a single small incision instead of 4-5 ports, flexible ureteroscopes with deflection angles and 270 degrees accessing the hard areas of the kidneys, and holmium laser lithotripsy systems that can fragment the stones with a 95% success rate, irrespective of composition, have been introduced due to technological advancements.

• Technological Innovation in Laser and Energy-Based Devices:

Laser technology and energy based surgery equipment advances have created a revolution in the treatment of urology by increasing treatment options, enhancing better outcomes, and creating new segments in the market. The gold standard of lithotripsy and soft tissue ablation is holmium laser systems. However, in 2024, the world had over 450,000 procedures annually with holmium:YAG lasers to fragment stones of any composition with a 92-98% success rate. Commercialized in 2018-2020, Thulium fiber lasers have a number of benefits. They have smaller fiber diameters, hence smaller endoscopes. They are capable of providing the sustained wave or pulse energy and leave flexibility to the surgeons. There is increased efficiency in energy delivery, which reduces 25-35 seconds of procedure time with holmium systems.

The world urology holmium laser market was estimated at USD 385 million in 2024 and is estimated to increase by 8.4% as more markets are embracing the technology. New lasers known as Holmium (HoLEP) and thulium (ThuLEP) lasers are used as an alternative to transurethral resection of the prostate. They excise all adenomas of all sizes of the prostates. In 94% of the cases, blood loss is less than 50 ml. The time spent with catheters reduces to less than 24 hours in 2-4 days. Vaporization of laser that utilizes potassium-titanyl-phosphate (KTP) lasers (green light laser vaporization) offers a bloodless cutting method, particularly in patients who are on anticoagulants.

The number of such procedures carried out all over the world is more than 180,000 per annum. Transurethral resection has been made to be done using bipolar energy devices which can be used to algorithmically saline irrigate rather than glycine solutions. This removes the risk of hyponatremia that occurred in 1-2% of the classical TURP cases and resulted in severe complications. New energy platforms are comprised of combinations of ultrasonic, bipolar, and monopolar energies in one instrument. They provide more flexibility to surgeons and ease of switching instruments in complicated procedures.

• Expanding Healthcare Infrastructure in Emerging Markets:

The booming health care infrastructure, increased spending and increasing medical tourism in emerging economies offer significant prospects of growth to the urology instrument manufacturers. As of 2024, in China, the healthcare expenditure amounted to 1.2 trillion, which constituted 7.1% of the GDP.

The government has set a target of 8% by 2030 where 1,850 new hospitals will be supported, and the current ones will be upgraded with high-level equipment. In 2024, the market of medical devices in India was worth 11.8 billion. Urology equipment comprised 6.2% because 340 million individuals have urological issues, and as a result of the Ayushman Bharat program, which provides health coverage to 500 million people, this figure will grow.

The countries in ASEAN have invested USD 48 billion in healthcare infrastructure 2020-2024. They opened urology centers in Thailand, Malaysia, Singapore, and Vietnam. Urological medical tourism has been increasing at an alarming rate: in 2024, 180,000 procedures were performed on foreign patients in India, 95,000 medical tourists in Thailand received treatment for kidney stones and prostate conditions, and 72,000 urology patients in Turkey came to seek affordable treatment.

The difference in cost is huge: a prostatectomy will cost 45,000-75,000 in the United States but 8,000-15,000 in India or Thailand, and the results are similar at recognized hospitals. Government programs to increase local production of medical devices include the Production Linked Incentive scheme in India, which allocated USD 1.4 billion to the local manufacturing industry, Made in China 2025 in china, with a 50% import substitution goal, and the Brazil Health Industrial Complex, a plan to establish local production. Those programs may interfere with the markets which are dominated by imports, and increase the use of instruments by means of lower prices.

What are the Major Advances Changing the Urology Surgical Instruments Market Today

• Robotic Surgical Platform Evolution and Market Expansion:

Advancements of robotic surgical systems outside the da Vinci monopoly have allowed competition, innovation and increased availability of robot-assisted urological surgery. The da Vinci systems at Intuitive Surgical have done more than 12 million operations since the FDA clearance in 2000 with an installed base of 7,544 systems worldwide at the end of 2024. The da Vinci Xi and X systems which were introduced in 2014-2019 have better visualization with in-built fluorescence imaging, have a larger surgical workspace with boom-mounted arms and operate with minimized workflows of 5-8 minutes setup time (versus 15-20 minutes) compared with earlier models. Competition In 2024, competition began with the Hugo RAS system by the company Medtronic cleared in 2024, which has a modular design and independent arm carts priced 30-40% lower than da Vinci systems, potentially making robotic surgery affordable to mid-sized hospitals.

The Versius system of CMR Surgical is approved in Europe and awaiting approval from the FDA that offers a reduced footprint, portable design, and per-procedure pricing models in comparison with traditional capital purchases. The Ottava platform will simplify operation and reduce the cost structure, as Johnson & Johnson projects, which is set to go online in 2026, will be combined with the advanced imaging and energy devices produced by the company. In 2024, the urology surgical robotics market globally had reached 2.8 billion, but this was expected to grow to over 6.2 billion in the year 2030 with the prices of the systems reducing, the clinical evidence growing, and the training infrastructure growing. The next advance is single-port robotic systems, with Intuitive making the da Vinci SP system eligible to perform urological surgery where surgery can be done through a 25mm incision with better cosmetic results and a lower average of 2.3/10 postoperative pain scores than with multiport systems.

• Flexible Digital Ureteroscopy and Advanced Imaging:

Flexible ureteroscopes with the addition of digital imaging sensors, enhanced deflection, and greater resilience have enabled the revolution in kidney stone and upper tract pathology treatment. The use of traditional fiberoptic ureteroscopes, with their fragile fibers, low image quality and average costs of repair of about 850-1200 per scope, has been mostly replaced by the use of digital scopes that have high definition images and high image transmission with built-in documentation features. Manufacturers such as Olympus, Karl Storz, and Stryker have 1080p or 4K resolution images powered by 90,000-400,000 pixel sensors that have greatly enhanced the visualization of small stones, subtle mucosal lesions, and anatomy. Deflection performance has been enhanced from older designs of 180-210 degrees to 270-300 degrees of current generation scopes and gives it access to all calyces with challenging lower pole anatomy in 96% of cases compared with 78% with old technology.

The issue of scope durability is resolved with the introduction of disposable digital ureteroscopes by such companies as Boston Scientific, Pusen Medical and NeoScope, which cost between 850-1500 per procedure compared to the 25,000-45,000 cost of reusable scopes, which need 30-50 applications to be economically justified. Market research will show that the disposable ureteroscopes will attain 18% of the market in 2024 and are expected to hit 35% in 2028 when healthcare systems will value the removed reprocessing costs, assured image quality and zero repair costs. The improved imaging modalities such as narrow-band imaging, photodynamic diagnosis and confocal laser endomicroscopy facilitates improved tumor detection, and research has indicated that NBI can reduce recurrence due to lesions that are not detected by the white light cystoscopy by 22-28%.

• Artificial Intelligence Integration in Surgical Planning and Execution:

The use of artificial intelligence in urology is changing the preoperative planning, intraoperative instructions, and evaluation of surgical skills with the help of sophisticated imaging analysis, predictive modeling, and real-time decision support. Prediction of kidney stone composition using AI algorithms on the basis of CT scans is able to predict and classify stones (uric acid, calcium oxalate, and cystine) with 87-92% accuracy before intervention: this allows optimization of the treatment modality and prevents unsuccessful procedures by 34% based on multi-institutional studies.

Machine learning systems that process 250,000 prostate MRI scans have achieved 94% sensitivity and 89% specificity in detecting clinically significant prostate cancer, which is even better than radiologists, and have led to a 28-35 reduction in unnecessary biopsies. Robotic systems and laparoscopic systems with intraoperative AI guidance systems enable real-time tissue detection, anatomical visualization, and preventive measures in situations when instruments are near vital organs such as blood vessels, nerves, and organs on the periphery. Researchers at the University of California created AI systems that watch surgical video footage and forecast postoperative complications with 76% accuracy using intraoperative events so that they could be prevented and dealt with early. Surgical skill AI systems will rate surgeon performance in 38 different measures, such as the economy of movement, instrument handling efficiency, tissue trauma, and procedure flow, which will objectively give a training program and credentialing feedback. The surgical instrumentation AI market is projected to reach 485 million dollars in 2024 and is projected to increase by 24.3% annually as hospitals invest in data infrastructure, surgeons adopt decision support technology, and reimbursement schemes progressively incentivize quality performance over quantity of procedures.

• Three-Dimensional Printing and Personalized Surgical Instruments:

Additive manufacturing technologies allow designing patient-specific anatomical models to use in surgical planning, designing customized instruments to fit the anatomy of each patient, and rapidly prototyping new designs of devices. Surgeons can rehearse complex partial nephrectomy and plan the best approach angles and recognize vascular anatomy on 3-dimensional printing of kidney models based on CT or MRI data with 98% correlation to intraoperative anatomy. Research shows that the use of 3D models helps shorten the time of operation by 18-24 seconds, warm ischemia by 22 seconds, and decrease the positive surgical margin rates of partial nephrectomy from 7.2 to 2.8%. Robotic partial nephrectomy Custom surgical guides depict accurate resection margins, less healthy tissue loss, and complete tumor resection with margin positivity rates less than 2%. Stone models of patients can be tested to test laser settings, basket configurations, and fragmentation techniques, even prior to actual procedures, resulting in better efficiency and 40-percent less radiation exposure due to fluoroscopy analysis of procedures.

In 2024, the 3D printing market in surgery had reached 1.8 billion dollars across the world and urology constituted 12% of all applications. The development of bioprinting is now such that it is capable of producing tissue-engineered patches of the bladder and urethral reconstructions, and even whole organs, and researchers at the University of Wake Forest have managed to implant lab-grown bladders into 7 patients with over 8 years of successful pain-free operation.

Report Scope

Regional Analysis

How Big is the North America Market Size?

The North America urology surgical instruments market size is estimated at USD 3.66 billion in 2025 and is projected to reach approximately USD 7.28 billion by 2035, with a 9.0% CAGR from 2026 to 2035.

Why did North America Dominate the Market in 2025?

The North America is top with a market share of 41 in 2025 because of the highest volumes of urological procedures with 2.8 million surgeries in US annually, The best healthcare infrastructure with 1,200 hospitals providing full scale urology services, the good presence of the major manufacturers such as Intuitive Surgical and Boston Scientific, the good reimbursement with Medicare paying 95% of the urological procedures and the installations of innovative technologies such as robotic surgery with 4,200 da Vinci systems.

The American Urological Association has 23,000 urologists in the country, who carry out 85% of the procedures using minimally invasive or robotic procedures. In the United States, healthcare urologic expenditures in 2024 totaled 28.4 billion, with 24% of the expenditure going to surgical instruments and devices. The directly proportional correlation between aging population of 56 million Americans aged above 65 and the projected 82 million above 65 and the prostate disease burden of 90% of men above 80 and the urinary incontinence burden of 40% of women above 65 are directly attributable to the aging population.

What is the Size of the U.S. Market?

The estimate of the market size of urology surgical instruments in the U.S. is USD 3.31 billion in the year 2025 and it is expected to rise by 8.9% between 2026-2035.

Why is Asia Pacific Experiencing Rapid Growth?

Asia Pacific shows the highest growth of 11.7% CAGR between 2026 and 2035 due to a huge population base of 4.6 billion people, with 340 million having urological problems, rapidly growing healthcare infrastructure, with 1850 hospitals being added in China and 620 specialized urology centers in India; rising healthcare expenditure of up to 1.2 trillion in China and 280 billion in India, rising middle classes with access to private healthcare and 180,000 urology patients in India. The efforts of the government, such as the Healthy China 2030 program that allocates funds to help manage chronic diseases in China and the Ayushman Bharat program that provides surgery coverage to 500 million citizens of India, increase access to surgery. Chinese domestic production manufactures cost effective instruments at 40-60% lower prices compared to the western counterparts yet of international quality to widen market access.

Why is Europe Focusing on Cost-Effectiveness?

Europe continues to have a high market share of up to $2.84 billion in 2025, which is marked by universal healthcare systems that focus on cost-effectiveness, health technology assessment criteria prior to reimbursement approval, the inclination to enact established technologies in lieu of new technologies and robust regulatory frameworks through the European Medical Device Regulation. The European nations have a total of 1.9 million urological operations per year with Germany counting 420,000 operations, France around 380,000 operations and the United Kingdom around 340,000 operations. The aging population of Europe with 201 million aged 60+ and 30% of the population aged 60 and above predicted to be over 65 by the year 2040 is compelling the rising volumes of procedures. The urologists in Europe have begun to use one-use tools to control the infection, and the uptake of disposable ureteroscopes has reached 24% in 2024 compared with 18% in the rest of the world.

Top Players in the Market and Their Offerings

• Intuitive Surgical Inc.

• Boston Scientific Corporation

• Karl Storz SE & Co. KG

• Olympus Corporation

• Stryker Corporation

• Richard Wolf GmbH

• Cook Medical

• Coloplast A/S

• Medtronic plc

• Teleflex Incorporated

• B. Braun Melsungen AG

• ConMed Corporation

• Others

Key Developments

• In September 2025: Intuitive Surgical unveiled the da Vinci 5 surgical system. It includes an improved vision, force feedback, and AI-enhanced guidance. It is the largest improvement since 2014, and they plan to launch in specific markets by Q4 2025.

• In December 2025: Medtronic received an FDA approval on the Hugo RAS urological procedure system. It is priced 35% less than da Vinci systems, and this could open access to robotic surgery to more than 800 hospitals.

These strategic activities have allowed companies to strengthen market positions, expand product offerings, enhance technological capabilities, and capitalize on growth opportunities within the expanding market.

The Urology Surgical Instruments Market is segmented as follows:

By Product Type

• Endoscopes

  • Cystoscopes

  • Ureteroscopes

  • Nephroscopes

• Lasers

  • Holmium Lasers

  • Thulium Lasers

  • Green Light Lasers

• Dialysis Devices

• Endovision Systems

• Peripheral Instruments

• Consumables & Accessories

By Application

• Kidney Diseases

• Urinary Stones

• Benign Prostatic Hyperplasia

• Urinary Incontinence

• Pelvic Organ Prolapse

• Oncology

• Others

By End User

• Hospitals

• Ambulatory Surgical Centers

• Specialty Clinics

• Others

By Surgery Type

• Open Surgery

• Minimally Invasive Surgery

• Robot-Assisted Surgery

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America